The present disclosure, relates, in general to methods for treating solid tumors comprising administering a drug-linker-antibody conjugate, wherein the drug is a tubulin disrupting agent.

The present disclosure provides methods of treating lymphoid malignancies such as B cell malignancies using a BTK inhibitor in the described therapeutic regimens.

Described herein are polypeptides and antibodies comprising a variant Fc region. The variant Fc region provides for stabilized Fc-Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, while at the same time also having decreased complement-dependent cytotoxicity (CDC) and may also have decreased activation of other effector functions resulting from one or more amino acid modifications in the Fc region.

The present invention encompasses methods for reducing the number of target cells in a subject, such as cancer cells. The methods include administration of genetically-modified human immune cells expressing a chimeric antigen receptor or exogenous T cell receptor, which have specificity for an antigen on the target cells. Administration of the genetically-modified immune cells is preceded by the administration of a tolerance regimen, followed by administration of a lymphodepletion regimen, to improve efficacy of the therapy and persistence of the cells in vivo.

The present invention encompasses methods for reducing the number of target cells in a subject, such as cancer cells. The methods include administration of genetically-modified human immune cells expressing a chimeric antigen receptor or exogenous T cell receptor, which have specificity for an antigen on the target cells Administration of the genetically-modified immune cells can be preceded by the administration of a lymphodepletion region and/or an immunosuppression regimen, to improve efficacy of the therapy and persistence of the cells in vivo.

Methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject, the method comprising a step of administering a recombinant hGMCSF antagonist to the subject, wherein said administering inhibits or reduces the incidence or the severity of immunotherapy-related toxicity in said subject, are provided. An hGMCSF antagonist for use in methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject also are provided.

In one aspect, the present disclosure provides targeted complement-activating molecules comprising a target-binding domain and a complement-activating serine protease effector domain. In some embodiments, the target-binding domain is derived from an antibody or an antigen-binding fragment thereof. Also provided are compositions and methods for treating cancer, autoimmune disease, or microbial infection, including bacterial, viral, fungal, or parasitic infection, using targeted complement-activating molecules.

The present invention relates to treatment of relapsing and progressive forms of multiple sclerosis using a humanized anti-human CD52 IgG.sub.1 monoclonal antibody.

The present invention provides a variety of methods for the identification and/or treatment of subjects that are at risk for developing life-threatening complications of SARS-CoV-2 infection and other infections. Such methods involve determining if a subject has clonal hematopoiesis.

The disclosure is directed to precision dosing regimens to achieve a target concentration of alemtuzumab in a subject of between about 0.15 μg/mL-about 0.6 μg/mL at day 0, or the day of a transplantation event involving allogeneic hematopoietic cells. The disclosure is also directed to methods of increasing the percentage of a patient population having a concentration of alemtuzumab of between about 0.15 μg/mL-about 0.6 μg/mL at day 0.